

Research Article

Cite this article: Cardoso M, Prata I, Rebelo I, Nunes T, Pires A, Carneiro C and Bexiga R (2022). Antimicrobial (ESBL) resistance genes in faecal *E. coli* of calves fed waste milk with antimicrobial residues. *Journal of Dairy Research* **89**, 259–264. <https://doi.org/10.1017/S0022029922000486>

Received: 22 July 2021

Revised: 1 April 2022

Accepted: 16 April 2022

First published online: 30 August 2022

Keywords:

Antimicrobial; calves; *E. coli*; ESBL; waste milk

Author for correspondence:

Ricardo Bexiga,

Email: ricardobexiga@fmv.ulisboa.pt

Antimicrobial (ESBL) resistance genes in faecal *E. coli* of calves fed waste milk with antimicrobial residues

Manuel Cardoso^{1,2}, Inês Prata^{1,2,3}, Inês Rebelo^{1,2}, Telmo Nunes^{1,2}, Ana Pires^{1,2}, Carla Carneiro^{1,2} and Ricardo Bexiga^{1,2}

¹Faculty of Veterinary Medicine, CIISA – Centre for Interdisciplinary Research in Animal Health, University of Lisbon, Lisbon, Portugal; ²Faculty of Veterinary Medicine, Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), University of Lisbon, Lisbon, Portugal and ³HVME – Hospital Veterinário Muralha de Évora, Évora, Portugal

Abstract

This research paper aimed to evaluate the association between feeding waste milk to calves and the occurrence of antimicrobial multi-resistance by extended spectrum β -lactamase (ESBL) enzymes through determining their production by *E. coli* isolates from 32 dairy farms. Among β -lactamase enzymes, ESBL provide resistance to a wide variety of β -lactam antimicrobials including penicillin and 2nd, 3rd and 4th generation cephalosporins. Feeding waste milk to calves has been observed to lead to increased antimicrobial resistance in faecal isolates of calves. In each farm included in this study, faecal samples were collected from the rectum of five healthy calves in the first month of life and pooled into a single container. Five isolates from each pool were selected and confirmed to be *E. coli* by amplification of the 16S rRNA gene. ESBL production was confirmed phenotypically on 148 isolates from 31 farms by use of the double-disk synergy test. Genotypic confirmation of ESBL production was performed by PCR for the genes blaCTX-M-1, -2, -8, -9 and blaCMY-2. A questionnaire was also performed and a mixed logistic regression model was used to identify risk factors for the occurrence of antimicrobial resistance. A negative binomial regression model was also used, in order to assess whether there was any association between certain farm management practices and the number of ESBL-producing *E. coli* isolates from each farm. Phenotypic confirmation of ESBL production was obtained on 40 *E. coli* isolates from 15 farms (48.4%), whereas genotypic confirmation was obtained on 55 isolates from 20 farms (64.5%). The use of three or more different intramammary antimicrobials to treat mastitis within the previous year significantly impacted the number of ESBL-producing *E. coli* isolates; on farms that did so, there were more isolates in which ESBL-producing *E. coli* was present, when compared to farms that had used less formulations within the same time span.

Beta-lactamases are enzymes capable of hydrolysing β -lactam antimicrobials, conferring resistance to Gram-negative bacteria. Among β -lactamase enzymes, the extended-spectrum β -lactamase enzymes (ESBL) have been under considerable focus because they provide resistance to a wide variety of β -lactam antimicrobials including penicillin and 2nd, 3rd and 4th generation cephalosporins and aztreonam (Seiffert *et al.*, 2013). Infections caused by Gram-negative bacteria harbouring these enzymes are challenging to treat and have increased in incidence in the human population (McDanel *et al.*, 2017), as well as in the dairy cattle population (Davis *et al.*, 2015). Despite limited evidence of transmission of ESBL-production from animal reservoirs to humans, the increasing gene pool from which pathogenic bacteria can pick up ESBL is a cause for concern (Madec *et al.*, 2017).

A specific group of ESBL, known as CTX-M, due to their capacity to hydrolyse cefotaxime (CTX), has been reported as the predominant type of ESBL (Xia *et al.*, 2014; Bevan *et al.*, 2017), and includes 5 subgroups (CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, CTX-M-25) and over 120 variants (D'Andrea *et al.*, 2013). There are also plasmid-mediated β -lactamase enzymes (pAmpC) produced by *E. coli*, of which the most frequently reported is the CMY type, that typically confers antimicrobial resistance to cephamycins (Shin *et al.*, 2017). There is evidence suggesting transfer of the CMY-2 plasmid between different bacterial species and even between food animals and humans (Winokur *et al.*, 2001), therefore, their isolation from farm animal origins is particularly relevant from a Public Health point of view.

Waste milk (Brunton *et al.*, 2012; Duse *et al.*, 2013), is a mixture of excess colostrum, transition milk and non-saleable milk from cows that have been or are still being treated with antimicrobials or other substances with a milk withdrawal period. Feeding calves with waste milk may represent an economic benefit for farmers not only because it leads to savings in milk replacer, but also because feeding whole milk has been shown to lead to higher growth

rates than feeding milk replacer with the same gross composition (Lee *et al.*, 2009). This practice may, however, present a risk for calves due to the potential infection with pathogens, including *Mycobacterium avium* subs. *paratuberculosis* leading to the spread of paratuberculosis if the milk is not subject to pasteurization (Leão *et al.*, 2017).

Exposing bacteria to concentrations of antimicrobials well below the minimum inhibitory concentrations has been shown to select for resistant bacteria (Gullberg *et al.*, 2011). Waste milk may contain low concentrations of one or more antimicrobials, which may result in selection favouring antimicrobial resistance in enteric bacteria. Feeding calves with waste milk was observed to lead to increased antimicrobial resistance in faecal isolates (Aust *et al.*, 2013) and increased concerns about this potential problem has led European authorities to evaluate the risks and to recommend possible mitigation strategies (EFSA Panel on Biological Hazards (BIOHAZ), 2017).

This study aims to evaluate potential risk factors for the occurrence of antimicrobial multi-resistance by extended spectrum β -lactamase enzymes through determining ESBL production by *E. coli* isolates from 32 dairy farms.

Materials and methods

Sample collection and isolate identification

A group of 32 commercial dairy farms located in mainland Portugal, supported by three different veterinary practices, was selected to participate in this study. Farms ranged in size from 16 to 715 lactating animals, with a mean size of 151 lactating animals, with zero grazing and feeding largely being based on maize silage and ryegrass silage. In each farm, faecal samples were collected from the rectum of five healthy calves in the first month of life and 1 g of each sample was pooled into a single container. The pooled faecal sample was then mixed with a 9 ml solution of 0.9% NaCl, and 10 μ l of the suspension was plated onto MacConkey Agar and incubated at 37°C overnight. Whenever possible, five lactose-positive colonies were selected per plate and further inoculated onto sheep blood agar and incubated overnight at 37°C. These colonies were submitted to biochemical identification by use of the IMViC test – Indole, Methyl red, Voges-Proskauer, Citrate (Quinn *et al.*, 1994), leading to 156 isolates presumptively identified as *E. coli*. This identification was then confirmed genotypically by amplification of the 16s rRNA gene (Chen *et al.*, 2003).

Determination of ESBL production

Phenotypic determination of ESBL production was performed according to the double-disk synergy test as defined by CLSI (2017). Briefly, each isolate confirmed genotypically as *E. coli* ($n = 148$) was submitted to an antimicrobial susceptibility test by the disk diffusion (Kirby-Bauer) method, with cefotaxime (CTX, 30 μ g) and ceftazidime (CAZ, 30 μ g). Results were interpreted according to criteria defined by the Clinical and Laboratory Standards Institute (CLSI, 2017). Isolates resistant to CTX and/or CAZ were submitted to a subsequent antimicrobial susceptibility test for phenotypic confirmation of ESBL production (CLSI, 2017). In this second test, 30 min prior to the CTX and CAZ disks being positioned on the plates, each paper disk was impregnated with a 10 μ l suspension of potassium clavulanate (1 mg/ml reconstituted in phosphate-buffered saline). After a 24-h

incubation period at 37°C, results were once more interpreted according to criteria defined by CLSI (2017). Phenotypic confirmation of ESBL production was evidenced by an increase in zone diameters of 5 mm or more for the test including clavulanate in comparison with the test without it.

Each isolate confirmed genotypically as *E. coli* was submitted to genotypic evaluation of ESBL production capability through conventional PCR, for the genes blaCTX-M and blaCMY-2. The test was performed using the primers (shown in online Supplementary Table S1) that were used by Yan *et al.* (2004) and Shahid *et al.* (2014). The 50 μ l final volume included 2 μ l of each primer (10 μ M), with the exception of blaCTX-M-8, for which 4 μ l of each primer (10 μ M) were used. Amplification reactions were performed in a VWR® Thermocycler Doppler, with distinct conditions for CTX-M and CMY-2. The first group was submitted to an initial denaturation at 94°C (7 min); 35 cycles of 94°C (50 s), 50°C (40 s) and 72°C (2 min), with a final extension at 72°C (5 min). For the second group, initial denaturation was performed at 94°C for 3 min, with 35 cycles of 94°C (1 min), 55°C (1 min) and 72°C (1 min), with a final extension at 72°C (7 min). Observation of amplification products was performed using the Chemidoc XRS + (Bio-Rad®Molecular Imager) equipment, with use of the Ladder V (NZYTech®) reference for the CTX-M group, and the Ladder VI (NZYTech®) reference for the CMY-2 group. Positive control isolates were kindly provided by Dr Lina Cavaco, National Food Institute, Technical University of Denmark. Both phenotypic and genotypic processes for the identification of ESBL production are summarized in Figure 1.

Questionnaire

A questionnaire was performed on all participating farms, undertaken by three different veterinarians, one from each practice. The questionnaire included questions regarding potential risk factors for the emergence of antimicrobial resistance, including feeding waste milk to calves, type of waste milk being fed (during antimicrobial treatment, during withdrawal period for treatment, from cows with mastitis or with high somatic cell counts), if the waste milk underwent any processing (such as pasteurization), use of preventive antimicrobial medicines fed to calves through milk, number of different intramammary tubes with antimicrobial drugs (different active substances) used on farm within the previous year to treat mastitis, if oral, systemic or both forms of antimicrobials were used for the treatment of diarrhoea in calves and if farms were open with respect to buying in animals.

Statistical analysis

A univariable logistic regression analysis was performed in order to understand if any of the considered risk factors (chosen considering the information provided by the questionnaire) had a significant impact on the presence of ESBL-producing *E. coli*. Each risk factor was used as an independent (or explanatory) variable, and the outcome variable was whether or not ESBL-producing *E. coli* was identified (on each farm) through genotypic confirmation. Each farm was regarded as one statistical unit.

Following this, the aim was to understand if there was any association between the aforementioned risk factors and the number of *E. coli* isolates from each farm that were able to produce ESBL. For this, a univariable negative binomial regression analysis was performed, in which the outcome variable was the number of




Fig. 1. Summary of the phenotypical and genotypical detection of ESBL production (and its results), and numbers of each type of ESBL among all *E. coli* isolates. AST, Antimicrobial susceptibility test. PCR, Polymerase chain reaction. CTX, cefotaxime. CAZ, ceftazidime. ESBL, Extended Spectrum Betalactamase. CTX.M.1, CTX.M.2, CTX.M.8, CTX.M.9, CMY.2, are the different types of ESBL identified.




Fig. 2. Histogram representing the distribution of the number of ESBL-producing *E. coli* isolates identified in each farm.

E. coli isolates from each farm that were positive to ESBL. This analysis was performed considering each of the risk factors retrieved from the questionnaire separately, as an explanatory variable. These statistical procedures were performed using the software R®, version 4.1.2 and R Studio; the STATS package was used for the logistic regression procedure, and the MASS package was used to conduct the negative binomial regression analysis.

Results

Confirmation of ESBL production

Out of 156 isolates from 32 dairy farms, 148 isolates from 31 farms were confirmed to be *E. coli*. These were all submitted to an initial antimicrobial susceptibility test with CTX and CAZ, of which 41 isolates (27.7%) from 16 farms (51.6%) were resistant. A second susceptibility test performed after the inclusion of clavulanate in the test media, revealed that phenotypic production of ESBL occurred in 40 isolates from 15 farms (48.4%), with only one resistant isolate not being an ESBL producer.

Based on the genotypic evaluation, there were ESBL producing isolates on 20 farms (64.5%). These results and the processes for phenotypic and genotypic identification of ESBL production are summarized in Figure 1. Figure 2 displays the distribution of the number of *E. coli* isolates, from each farm, that were genotypically identified as being ESBL-producing. Fifteen out of these 20 farms showed only one type of ESBL group, whereas 4 farms showed two different types and 1 farm had three different ESBL groups. Individual farm data are presented in online Supplementary Table S2.

There was a significant association ($P < 0.05$) between phenotypic and genotypic results of ESBL production; on 20 farms the results were coherent, whereas on 6 farms there were genotypically positive results with a negative phenotype, and on a single farm there was a positive phenotype and negative genotype.

Questionnaire

The questionnaire revealed that 28 out of 31 farms (90.3%) fed waste milk to calves. On all of the farms that had this practice,

Table 1. Results of the univariable logistic regression analysis

Risk factor	Estimate	SE	Z-statistic	P-value
Feeds waste milk	-0.105	1.287	-0.082	0.935
Waste milk from mastitis	-0.105	1.287	-0.082	0.935
Waste milk from withdrawal period	-0.105	1.287	-0.082	0.935
Waste milk from high cell count	0.588	0.758	0.775	0.438
Processing of waste milk	-16.04	2399.54	-0.007	0.995
Adds antimicrobials to milk	0.945	1.197	0.789	0.430
Treats diarrhoea with oral antimicrobials	0.965	0.775	1.245	0.213
Treats diarrhoea with systemic antimicrobials	-0.916	1.189	-0.771	0.441
Treats diarrhoea with oral and systemic antimicrobials	0.780	0.812	0.960	0.337
Buys-in animals	0.760	0.771	0.986	0.324
Three or more intramammary formulations used in previous year	0.965	0.775	1.245	0.213

SE, Standard error.

waste milk comprised milk from animals being treated with antimicrobials and milk originating from animals during the withdrawal period for antimicrobial treatment. For 17 of the farms, waste milk also included milk from animals with high somatic cell count.

On 7 of the 31 farms, an antimicrobial was added to milk, either waste milk or milk replacer, in a preventive way. The questionnaire also revealed that the number of different intramammary tubes used as treatment options for mastitis in the previous year varied from 1 to 7, considering different active substances or their combinations. Sixteen of the farms where the interview was conducted had made frequent use of 3 or more different intramammary formulations for this purpose. Fifteen (48.4%) farms bought in animals, 16 (51.6%) used oral antimicrobials to treat cases of neonatal diarrhoea, 26 (83.8%) used systemic antimicrobials and 12 (38.7%) farms used both oral and systemic antimicrobials to treat calves with diarrhoea. Results of individual farm questionnaires are presented in online Supplementary Tables S3 and S4.

Statistical analysis

According to the results of the univariate logistic regression analysis (Table 1), none of the analysed risk factors had a significant influence on the presence of ESBL-producing *E. coli* on farm. The negative binomial regression analysis (Table 2) identified the number of intramammary antimicrobial formulations used in the previous year to treat mastitis as being significantly associated with a higher number of ESBL-producing *E. coli* isolates detected. According to the results of this analysis, in farms that had used three or more different intramammary formulations to treat mastitis during the previous year, the number of ESBL-producing *E. coli* isolates being detected in the samples from their calves was expected to increase by a factor of 2.125 in comparison with farms that had not done so (given that, for a given farm, the other risk factors remained unchanged). This means that, in farms that have used that many intramammary formulations during that period, we estimate that the number of ESBL-producing *E. coli* isolated from their calves will be, on average, 112.5% higher compared to farms that had used less intramammary formulations

Discussion

Feeding waste milk to calves is a common practice among the farms that participated in the study, with 90.3% of the farms from which *E. coli* was sampled having it as part of their feeding routine. This has been reported in other parts of the world as well, including 48.2% of the farms in Canada (Vasseur *et al.*, 2010), 79% of the farms in Sweden (Duse *et al.*, 2013) and 83% of the farms in England and Wales (Brunton *et al.*, 2012).

In our study, none of the farm management practices addressed in the survey were found to be significant risk factors, per se, for the occurrence of ESBL-producing *E. coli*. However, we did find a significant association between having used a certain number of different intramammary antimicrobials in the previous year and the number of ESBL producing *E. coli* isolates detected. In farms that had used three or more different intramammary tubes to treat mastitis during the previous year, the number of ESBL-producing *E. coli* isolates being detected in the samples from their calves was expected to increase by a factor of 2.125 in comparison with farms that had not done so. Taking these results into account, we argue whether the number of ESBL-producing *E. coli* isolates detected in each farm could be an indicator of the intensity at which this microorganism is being excreted in that same farm, thus being a possible indicator of its prevalence. We find that further studies with larger samples are necessary to draw conclusions regarding this matter.

Mastitis is the main reason for the use of antimicrobials in dairy cattle (Kuipers *et al.*, 2016), and as such it will be the main driver for the generation of waste milk with antimicrobial residues. There are many licensed products for mastitis treatment, including 3rd and 4th generation cephalosporins, some of which have been reported as having the highest usages for mastitis treatment (Kuipers *et al.*, 2016). The use of many different intramammary tubes for the treatment of mastitis (instead of defined protocols with one or two treatment options) is contrary to good practice. The number of antimicrobials in each intramammary tube was not taken into account, even though there are intramammary tubes in the European market that contain up to four distinct antimicrobials, which might be relevant from the point of view of antimicrobial stewardship.

Feeding waste milk with antimicrobials to calves has been observed to increase the number of CTX-M-positive bacteria shed

Table 2. Results of the univariate negative binomial regression analysis, expressed as the exponential value of the regression coefficients

Risk factor		Exponential of the coefficient	LL of 95% CI	UL of 95% CI	P-value
Feeds waste milk	Intercept	1.667	0.467	5.886	0.929
		0.943	0.251	3.572	
Feeds waste milk from mastitis	Intercept	1.667	0.467	5.886	0.929
		0.943	0.251	3.572	
Feeds waste milk from withdrawal period	Intercept	1.667	0.467	5.886	0.929
		0.943	0.251	3.572	
Feeds waste milk with high cell count	Intercept	1.571	0.876	2.802	0.979
		1.010	0.463	2.208	
Processing of waste milk	Intercept	3.000	0.488	24.280	0.475
		0.506	0.060	3.253	
Adds antimicrobials to milk	Intercept	1.348	0.854	2.091	0.159
		1.929	0.773	4.894	
Treats diarrhoea with oral antimicrobials	Intercept	1.400	0.782	2.472	0.572
		1.250	0.577	2.725	
Treats diarrhoea with systemic antimicrobials	Intercept	2.000	0.805	5.045	0.572
		0.750	0.272	2.043	
Treats diarrhoea with oral and systemic antimicrobials	Intercept	1.579	0.958	2.592	0.995
		1.003	0.451	2.225	
Buys-in animals	Intercept	1.625	0.947	2.779	0.883
		0.943	0.433	2.052	
Three or more intramammary formulations used in previous year	Intercept	1.000	0.533	1.777	0.049
		2.125	1.016	4.585	

LL, lower limit; UL, upper limit; CI, confidence interval.

in faeces, leading to a longer excretion of such bacteria and a higher level of contamination of calf pens with CTX-M-positive *E. coli*, in comparison with feeding milk replacer (Brunton *et al.*, 2014). Several recent publications have found increased antimicrobial resistance in faecal *E. coli* from calves being fed waste milk with antimicrobial residues (Pereira *et al.*, 2014; Maynou *et al.*, 2017), but not necessarily in other bacterial species (Aust *et al.*, 2013). ESBL-producing *E. coli* has also been isolated from mastitic milk samples in a high proportion of samples (Ali *et al.*, 2016). Pasteurization of waste milk to render it safer from a microbiological point of view has been shown not to affect the presence of antimicrobials in waste milk (Jorgensen *et al.*, 2006). The presence of ESBL-producing *E. coli* in raw bulk tank milk seems to vary between publications (Geser *et al.*, 2012; Odenthal *et al.*, 2016) but in this case, pasteurization renders milk safe for human consumption.

The potential risks and mitigation strategies of feeding waste milk to calves have recently been critically reviewed by EFSA (2017). Several options are discussed in that document to prevent waste milk with antimicrobial residues being fed to calves. However, due to the economic constraints put on many dairy farmers, the use of waste milk to feed calves will probably continue to be a routine for many farmers. Use of on-farm testing systems to identify mastitis pathogens and target treatment decisions for mastitis has been shown to decrease antimicrobial use by 50% and decrease milk withdrawal times (Lago *et al.*, 2011). Using

such a strategy could thus reduce the amount of waste milk being generated, while allowing for important economical savings.

Simply not feeding waste milk to calves may not be sufficiently safe to be recommended either. If waste milk is not used to feed calves, it will generally be delivered to manure, which in itself might carry other dangers relating to the transfer of resistance genes horizontally to indigenous soil bacteria (Beneragama *et al.*, 2013). However, there is evidence that anaerobic digestion or composting of manure reduces the load of initial antimicrobial resistant bacteria (Youngquist *et al.*, 2016).

In conclusion, feeding waste milk to calves was performed in 90.3% of participating farms, and that included milk from animals under antimicrobial treatment, animals going through the withdrawal period of antimicrobial treatments and milk from animals with subclinical mastitis. None of the farm management practices analysed were significant risk factors for harbouring ESBL-producing *E. coli*. However, further statistical analysis suggested that farms that had used three or more different intramammary formulations to treat mastitis during the previous year would see an estimated increase of 112.5% in the number of ESBL-producing *E. coli* isolates being detected in the samples from their calves (provided that other risk factors remained equal).

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0022029922000486>

Acknowledgements. This research was funded by FCT-Fundação para a Ciência e Tecnologia, I.P. (Portugal) through Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA) project UIDB/00276/2020, Laboratório Associado para Ciência Animal e Veterinária (AL4AnimalS) project LA/P/0059/2020 and Magnomics. Doctor Lina Cavaco, National Food Institute, Technical University of Denmark, is acknowledged for kindly providing positive control isolates.

References

- Ali T, Rahman S, Zhang L, Shahid M, Zhang S, Liu G, Gao J and Han B (2016) ESBL-producing *Escherichia coli* from cows suffering mastitis in China contain clinical class 1 integrons with CTX-M linked to IS CR1. *Frontiers in Microbiology* 7, 1931.
- Aust V, Knappstein K, Kunz H-J, Kaspar H, Wallmann J and Kaske M (2013) Feeding untreated and pasteurized waste milk and bulk milk to calves: effects on calf performance, health status and antibiotic resistance of faecal bacteria. *Journal of Animal Physiology and Animal Nutrition* 97, 1091–1103.
- Beneragama N, Iwasaki M, Lateef SA, Yamashiro T, Ihara I and Umetsu K (2013) The survival of multidrug-resistant bacteria in thermophilic and mesophilic anaerobic co-digestion of dairy manure and waste milk. *Animal Science Journal* 84, 426–433.
- Bevan ER, Jones AM and Hawkey PM (2017) Global epidemiology of CTX-M β -lactamases: temporal and geographical shifts in genotype. *Journal of Antimicrobial Chemotherapy* 72, 2145–2155.
- Brunton LA, Duncan D, Coldham NG, Snow LC and Jones JR (2012) A survey of antimicrobial usage on dairy farms and waste milk feeding practices in England and Wales. *Veterinary Record* 171, 296.
- Brunton LA, Reeves HE, Snow LC and Jones JR (2014) A longitudinal field trial assessing the impact of feeding waste milk containing antibiotic residues on the prevalence of ESBL-producing *Escherichia coli* in calves. *Preventive Veterinary Medicine* 117, 403–412.
- Chen YMM, Wright PJ, Lee CS and Browning GF (2003) Uropathogenic virulence factors in isolates of *Escherichia coli* from clinical cases of canine pyometra and feces of healthy bitches. *Veterinary Microbiology* 94, 57–69.
- Clinical and Laboratory Standards Institute (CLSI) (2017) *Performance Standards for Antimicrobial Susceptibility Testing*, 27th Edn., Pennsylvania, USA: Clinical and Laboratory Standards Institute.
- D'Andrea MM, Arena F, Pallecchi L and Rossolini GM (2013) CTX-M-type β -lactamases: a successful story of antibiotic resistance. *International Journal of Medical Microbiology* 303, 305–317.
- Davis MA, Sisco WM, Jones LP, Moore DA, Ahmed S, Short DM and Besser TE (2015) Recent emergence of *Escherichia coli* with cephalosporin resistance conferred by *bla*_{CTX-M} on Washington state dairy farms. *Applied and Environmental Microbiology* 81, 4403–4410.
- Duse A, Waller KP, Emanuelson U, Unnerstad HE, Persson Y and Bengtsson B (2013) Farming practices in Sweden related to feeding milk and colostrum from cows treated with antimicrobials to dairy calves. *Acta Veterinaria Scandinavica* 55, 49.
- EFSA Panel on Biological Hazards (BIOHAZ) (2017) Risk for the development of Antimicrobial Resistance (AMR) due to feeding of calves with milk containing residues of antibiotics. *EFSA Journal* 15, 4665.
- Geser N, Stephan R and Hächler H (2012) Occurrence and characteristics of extended-spectrum β -lactamase (ESBL) producing Enterobacteriaceae in food producing animals, minced meat and raw milk. *BMC Veterinary Research* 8, 21. doi: 10.1186/1746-6148-8-2.
- Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D and Andersson DI (2011) Selection of resistant bacteria at very Low antibiotic concentrations. *PLoS Pathogens* 7, e1002158.
- Jorgensen MA, Hoffman PC and Nytes AJ (2006) A field survey of on-farm milk pasteurization efficacy. *The Professional Animal Scientist* 22, 472–476.
- Kuipers A, Koops WJ and Wemmenhove H (2016) Antibiotic use in dairy herds in the Netherlands from 2005 to 2012. *Journal of Dairy Science* 99, 1632–1648.
- Lago A, Godden SM, Bey R, Ruegg PL and Leslie K (2011) The selective treatment of clinical mastitis based on on-farm culture results: I. Effects on antibiotic use, milk withholding time, and short-term clinical and bacteriological outcomes. *Journal of Dairy Science* 94, 4441–4456.
- Leão C, Botelho A, Martins E, Aguiar C, Rebelo I, Nunes T and Bexiga R (2017) Presence of *Mycobacterium avium* subs. *paratuberculosis* DNA in milk used to feed calves in Portugal. *Journal of Dairy Research* 84, 124–127.
- Lee HJ, Khan MA, Lee WS, Yang SH, Kim SB, Ki KS, Kim HS, Ha JK and Choi YJ (2009) Influence of equalizing the gross composition of milk replacer to that of whole milk on the performance of Holstein calves. *Journal of Animal Science* 87, 1129–1137.
- Maced J-Y, Haenni M, Nordmann P and Poirel L (2017) Extended-spectrum β -lactamase/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans? *Clinical Microbiology and Infection* 23, 826–833.
- Maynou G, Migura-Garcia L, Chester-Jones H, Ziegler D, Bach A and Terré M (2017) Effects of feeding pasteurized waste milk to dairy calves on phenotypes and genotypes of antimicrobial resistance in fecal *Escherichia coli* isolates before and after weaning. *Journal of Dairy Science* 100, 7967–7979.
- McDaniel J, Schweizer M, Crabb V, Nelson R, Samore M, Khader K, Blevins AE, Diekema D, Chiang H-Y, Nair R and Perencevich E (2017) Incidence of extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella* infections in the United States: a systematic literature review. *Infection Control & Hospital Epidemiology* 38, 1209–1215.
- Ondenthal S, Akineden Ö and Usleber E (2016) Extended-spectrum β -lactamase producing Enterobacteriaceae in bulk tank milk from German dairy farms. *International Journal of Food Microbiology* 238, 72–78.
- Pereira RVV, Siler JD, Bicalho RC and Warnick LD (2014) In vivo selection of resistant *E. coli* after ingestion of milk with added drug residues. *PLoS ONE* 9, e115223.
- Quinn PJ, Carter ME, Carter GR and Ricketts SW (1994) Enterobacteriaceae. *Clinical Veterinary Microbiology*, 1st Edn. Maryland Heights, USA: Mosby, pp. 209–236.
- Seiffert SN, Hilty M, Perreten V and Endimiani A (2013) Extended-spectrum cephalosporin-resistant Gram-negative organisms in livestock: an emerging problem for human health? *Drug Resistance Updates* 16, 22–45.
- Shahid M, Al-Mahmeed A, Muradha MM, Qareeballa A, Eltahir MA, Tabbara KS, Ismael AY, Dar FK, Giha HA, Bindayna KM and Bindayna KM (2014) Characterization of cephalosporin-resistant clinical Enterobacteriaceae for CTX-M ESBLs in Bahrain. *Asian Pacific Journal of Tropical Medicine* 7, S212–S216.
- Shin SW, Jung M, Won HG, Belaynehe KM, Yoon IJ and Yoo HS (2017) Characteristics of transmissible CTX-M- and CMY-type β -lactamase-producing *Escherichia coli* isolates collected from pig and chicken farms in South Korea. *Journal of Microbiology and Biotechnology* 27, 1716–1723.
- Vasseur E, Boderas F, Cue RI, Lefebvre D, Pellerin D, Rushen J, Wade KM and de Passillé AM (2010) A survey of dairy calf management practices in Canada that affect animal welfare. *Journal of Dairy Science* 93, 1307–1316.
- Winokur PL, Vonstein DL, Hoffman LJ, Uhlenhopp EK and Doern GV (2001) Evidence for transfer of CMY-2 AmpC β -lactamase plasmids between *Escherichia coli* and *Salmonella* isolates from food animals and humans. *Antimicrobial Agents and Chemotherapy* 45, 2716–2722.
- Xia S, Fan X, Huang Z, Xia L, Xiao M, Chen R, Xu Y and Zhuo C (2014) Dominance of CTX-M-type extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* isolated from patients with community-onset and hospital-onset infection in China. *PLoS ONE* 9, 100707.
- Yan J-J, Hong C-Y, Ko W-C, Chen Y-J, Tsai S-H, Chuang C-L and Wu J-J (2004) Dissemination of bla_{CMY-2} among *Escherichia coli* isolates from food animals, retail ground meats, and humans in southern Taiwan. *Antimicrobial Agents and Chemotherapy* 48, 1353–1356.
- Youngquist CP, Mitchell SM and Cogger CG (2016) Fate of antibiotics and antibiotic resistance during digestion and composting: a review. *Journal of Environmental Quality* 45, 537–545.